Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rein Therapeutics, Inc.RNTX · Entity 7071 | Director | July 23, 2025 | July 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rein Therapeutics, Inc.
Report date July 23, 2025 · Filed July 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2035-07-22 | Direct | 17,500 |
Reported balance
After 2025-07-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-23 · Grant · Acquired 17,500 · Balance 17,500 F1: This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2025 Filed Jul 23, 2025 19:36 UTC | Rein Therapeutics, Inc. RNTX · Entity 7071 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0000950170-25-098039 · ownership.xml · derivative · entry 1 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2035-07-22 F1 · derivative.exercise_date: This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| December 02, 2024 Filed Dec 6, 2024 16:38 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0000950170-24-134160 · ownership.xml · derivative · entry 1 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-12-01 F1 · derivative.exercise_date: This option was granted on December 2, 2024. The shares underlying the option are scheduled to vest in full on December 2, 2025. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 16:06 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 2,725 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000950170-24-099834 · ownership.xml · derivative · entry 1 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,725 Underlying: Common Stock · 2,725 shares Expires 2034-08-19 F1 · derivative.exercise_date: This option was granted on August 20, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) August 20, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:05 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 2,725 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0000950170-24-023840 · ownership.xml · derivative · entry 1 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,725 Underlying: Common Stock · 2,725 shares Expires 2034-02-27 F1 · derivative.exercise_date: This option was granted on February 28, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) February 28, 2025 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| February 28, 2024 Filed Apr 10, 2024 16:15 UTC Amendment | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 2,725 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0000950170-24-043361 · ownership.xml · derivative · entry 1 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,725 Underlying: Common Stock · 2,725 shares Expires 2034-02-27 F1 · derivative.exercise_date: This option was granted on February 28, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) February 28, 2025 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 17:12 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 54,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000899243-22-023136 · doc4.xml · derivative · entry 1 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,500 Underlying: Common Stock · 54,500 shares Expires 2032-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 15, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 19:55 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 96,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000899243-21-024530 · doc4.xml · derivative · entry 1 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2021. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 15, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 16:30 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0000899243-20-017079 · doc4.xml · derivative · entry 1 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-06-16 F1 · derivative.exercise_date: This option was granted on June 17, 2020. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 17, 2021 or (ii) the date of the Issuer's 2021 Annual Meeting of Stockholders Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 16:31 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 5,800 | $1.22 | $7,076.00 |
DisclosureSEC source: 0000899243-20-016859 · doc4.xml · nonDerivative · entry 1 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,800 Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:05 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0000899243-19-017791 · doc4.xml · derivative · entry 1 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: This option was granted on June 19, 2019. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 19, 2020 or (ii) the date of the Issuer's 2020 Annual Meeting of Stockholders. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 18:16 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.02 | $0.00 |
DisclosureSEC source: 0000899243-18-017967 · doc4.xml · derivative · entry 1 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-20 F1 · derivative.exercise_date: This option was granted on June 21, 2018. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 21, 2019 or (ii) the date of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 18:20 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $12.09 | $0.00 |
DisclosureSEC source: 0000899243-17-022772 · doc4.xml · derivative · entry 1 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-09-25 F1 · derivative.exercise_date: This option was granted on September 26, 2017. The shares underlying the option are scheduled to vest in equal annual installments over three years from July 25, 2017. Read SEC document |
| July 05, 2017 Filed Jul 5, 2017 18:13 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries F Preferred Stock · Derivative | 3,705,882 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-017853 · doc4.xml · derivative · entry 8 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 372,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.nature: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd. Read SEC document |
| July 05, 2017 Filed Jul 5, 2017 18:13 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries E-3 Preferred Stock · Derivative | 2,293,829 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-017853 · doc4.xml · derivative · entry 7 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 230,837 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.nature: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd. Read SEC document |
| July 05, 2017 Filed Jul 5, 2017 18:13 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries E-2 Preferred Stock · Derivative | 2,644,558 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-017853 · doc4.xml · derivative · entry 6 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 266,132 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.nature: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd. Read SEC document |
| July 05, 2017 Filed Jul 5, 2017 18:13 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries D Preferred Stock · Derivative | 6,781,770 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-017853 · doc4.xml · derivative · entry 5 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 682,476 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.nature: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd. Read SEC document |
| July 05, 2017 Filed Jul 5, 2017 18:13 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries C-2 Preferred Stock · Derivative | 4,238,607 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-017853 · doc4.xml · derivative · entry 4 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 426,547 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.nature: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd. Read SEC document |
| July 05, 2017 Filed Jul 5, 2017 18:13 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries C Preferred Stock · Derivative | 2,967,025 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-017853 · doc4.xml · derivative · entry 3 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 298,583 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.nature: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd. Read SEC document |
| July 05, 2017 Filed Jul 5, 2017 18:13 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 266,667 | $15.00 | $4,000,005.00 |
DisclosureSEC source: 0000899243-17-017853 · doc4.xml · nonDerivative · entry 2 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,544,182 F3 · shares: Novartis Bioventures Ltd., a wholly-owned indirect subsidiary of Novartis AG, acquired 266,667 shares of Common Stock in the Issuer's initial public offering. F2 · ownership.nature: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd. Read SEC document |
| July 05, 2017 Filed Jul 5, 2017 18:13 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionCommon Stock | 2,277,515 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-017853 · doc4.xml · nonDerivative · entry 1 Ambros Reinhard J. · CIK 0001709690 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,277,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.nature: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The board of directors of Novartis Bioventures Ltd. has sole voting and investment power over such shares. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. The Reporting Person is an employee of a corporation that is affiliated with Novartis Bioventures Ltd., a position from which he will retire effective September 1, 2017. Dr. Ambros disclaims beneficial ownership of the shares held by Novartis Bioventures Ltd., except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis Bioventures Ltd. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.